All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 17:26:12 ON 25 NOV 2002

=> FIL REG

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 17:26:21 ON 25 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American-Chemical-Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 NOV 2002 HIGHEST RN 474353-54-3 DICTIONARY FILE UPDATES: 24 NOV 2002 HIGHEST RN 474353-54-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10081147.str

L1 STRUCTURE UPLOADED

=> d L1 HAS NO ANSWERS L1 STR

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam

SAMPLE SEARCH INITIATED 17:26:40 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 447 TO ITERATE

100.0% PROCESSED 447 ITERATIONS

14 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 7672 TO 10208 PROJECTED ANSWERS: 55 TO 503

L2 14 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 17:26:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 9236 TO ITERATE

100.0% PROCESSED 9236 ITERATIONS

340 ANSWERS

SEARCH TIME: 00.00.01

L3 340 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 140.28 140.49

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 17:26:49 ON 25 NOV 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Nov 2002 VOL 137 ISS 22 FILE LAST UPDATED: 24 Nov 2002 (20021124/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s 13 full

L4 10 L3

=> d l4 1-10 ibib abs hitstr

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2002 ACS

10081147

ACCESSION NUMBER:

2002:793619 CAPLUS

DOCUMENT NUMBER:

137:294870

TITLE:

Preparation of prodrugs of 3-(pyrrol-2-ylmethylidene)-

2-indolinones and activity as modulators of protein

kinases

INVENTOR(S):

Sun, Connie Li; Wei, Chung Chen; Tang, Peng Cho; Koenig, Marcel; Zhou, Yong; Vojkovsky, Tomas;

Nematalla, Asaad S.

PATENT ASSIGNEE(S):

Sugen, Inc., USA

SOURCE:

PCT Int. Appl., 194 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO. KII						DATE			A.	PPLI	CATI	ои ис	ο.	DATE				
	WO	2002081466			A:	1.	20021017			WO 2002-US11001 20020409									
		W:	ΑE,	AG,	AL,	AM,	AT,	ΑŲ,	ΑZ,	ΒA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
			CO,	CŔ,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KΡ,	KR,	ΚZ,	LC,	LK,	LR,	
			LS,	LT,	_LU_,_	LV,	_MA,	MD.,	_MG ,-	MK,=	MN,	−MW,	-MX-	MZ,	- NO ,-	-NZ,	-OM-	PH;	
			PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TN,	TR,	TT,	TZ,	
			UA,	UG,	US,	UZ,	VN,	YU,	ZA,	ZM,	ZW,	AM,	ΑZ,	BY,	KG,	KZ,	MD,	RU,	
			ТJ,	TM															
		RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	ŞL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑT,	BE,	CH,	
			CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	
			BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG	
PRIORITY APPLN. INFO.:									1	US 2	001-	2826	30P	P	2001	0409			
OTHER SOURCE(S):							MARPAT 137:294870												
GI																			

The present invention relates to pyrrole substituted 2-indolinone compds. AΒ (shown as I; e.g. 3-[1-(3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2oxo-2,3-dihydroindole-1-carbonyl chloride) and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer (no data). In I, R1 and R2 are independently H, halo, alkyl, alkylthio, nitro, trihalomethyl, hydroxy, hydroxyalkyl, alkoxy, cyano, aryl, heteroaryl, -C(O)R7 (R7 is alkyl, amino, hydroxy, alkoxy, aryl, heteroaryl, aryloxy, heteroaryloxy, heterocycle, and aminoalkylamino), -NR8R9, -NR8C(O)R9, -SO2R8, and -S(O)2NR8R9 (R8 and R9 are independently H, alkyl, aryl and heteroaryl, or R8 and R9 together with the N to which they are attached form a satd. heterocycloamino). R3 is H, alkyl, hydroxyalkyl, aminoalkyl, -C(O)R7, aryl, and heteroaryl; R4 is H, alkyl, -C(O)R7 aryl, and heteroaryl. R5 is H and -COR10 where R10 is alkyl, alkoxy, hydroxy, aryl,

Ι

aryloxy, heteroaryl, heterocycle, alkylamino, dialkylamino, or -NR11R12 where R11 is H or alkyl, and R12 is aminoalkyl, hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl, alkoxycarbonylalkyl, heteroaralkyl, or heterocyclylalkyl wherein the alkyl chain in aminoalkyl, heteroaralkyl, heteroaralkyl, or heterocyclylalkyl is optionally substituted with one or two hydroxy group(s); or R4 and R5 together form - (CH2)4- or -(CH2)mCO(CH2)n- wherein n is 0 to 3, provided that n+m is 3. R6 is: (c) -OR13 wherein R13 is alkyl, trifluoromethyl, carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, alkoxyalkyl, aryl, heteroaryl, heteroaralkyl, heterocyclyl, monosaccharides and heterocyclylalkyl wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxyalkyl, or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two C atoms in said alkyl chain are optionally replaced by O, -NR14- (R14 is H or alkyl), -S-, or -SO2-; or. (d) -NR15R16 where are R15 and R16 are independently H, alkyl, carboxyalkyl, alkoxyalkyl, aminoalkyl, phosphonooxyalkyl, sulfooxyalkyl, hydroxyalkyl, aryl, heteroaryl, heteroaralkyl, and heterocyclylalkyl; wherein the alkyl chain in carboxyalkyl, aminoalkyl, phosphonooxyalkyl, heteroaralkyl, heterocyclylalkyl, hydroxyalkyl, or alkoxyalkyl is optionally substituted with one or two hydroxy group(s) and further wherein one or two C atoms in the alkyl chain are optionally replaced by O, -- NR17--(R17-is-H-or-alkyl-), -- S-, -or -SO2-; -or -R15 and R16 together with the N atom to which they are attached form satd. or unsatd. heterocycloamino;. Although the methods of prepn. are not claimed, >80 example prepns. are included, both of I and the unprotected version of I in which the C(O)R6 group has been replaced by H. 356068-94-5P, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)ylidenemethyl) -2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of prodrugs of (pyrrolylmethylidene)indolinones and activity as modulators of protein kinases)

RN 356068-94-5 CAPLUS

CN

1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

IT 326914-13-0P, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

```
342641-60-5P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-
TT
    2,4-dimethyl-1H-pyrrole=3-carboxylic-acid-(2-dimethylaminoethyl)amide
    342641-61-6P, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-
    ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide
    342641-62-7P, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-
    2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide
    342641-63-8P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-
    2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
    342641-64-9P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-
    2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide
    342641-65-0P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-
    2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-(imidazol-1-yl)propyl)amide
    342641-66-1P, 5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-
    ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
     (2-dimethylaminoethyl) amide 342641-67-2P, 5-[6-(3-Methoxyphenyl)-
    2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-
    carboxylic acid (2-dimethylaminoethyl)amide 342641-68-3P,
    2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-
    pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 342641-69-4P
     , 2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-
    pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide
    342641-70-7P, 2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-
    ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-(imidazol-1-yl)propyl)amide
    342641-71-8P, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-
    ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
    342641-72-9P, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-
    ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-
    yl)ethyl)amide 342641-73-0P, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-
    dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid
     (3-(imidazol-1-yl)propyl)amide 342641-74-1P,
    5-[6-(3,5-Dichlorophenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-
    dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
    342641-75-2P, 2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-
    dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid
     (2-diethylaminoethyl) amide 342641-76-3P, 2,4-Dimethyl-5-(2-oxo-6-
    pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic
    acid (2-(pyrrolidin-1-yl)ethyl)amide 342641-77-4P,
    2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-
    pyrrole-3-carboxylic acid (3-dimethylaminopropyl)amide
    342641-78-5P, 2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-
    ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-dimethylaminopropyl)amide
```

```
342641-79-6P, 2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-
ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide
342641-80-9P, 2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-
ylidenemethyl) -1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl) amide
342641-81-0P, 3-[4-(3-Diethylaminopropylcarbamoy1)-3,5-dimethyl-1H-
pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-4-carboxylic acid
(3-chloro-4-methoxyphenyl) amide 342641-82-1P,
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-
3-carboxylic acid (3-diethylaminopropyl)amide 342641-83-2P,
5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-
pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 342641-84-3P
, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-
pyrrole-3-carboxylic acid (3-diethylaminopropyl) amide 342641-85-4P
, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-
pyrrole-3-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide
342641-87-6P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-
2,4-dimethyl-1H-pyrrole-3-carboxylic acid (pyridin-4-ylmethyl)amide
342641-88-7P, 5-[6-(4-Butylphenyl)-2-oxo-1,2-dihydroindol-3-
ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-(pyrrolidin-1-yl)ethyl)amide 342641-89-8P,
5-[6-(5-Isopropyl-2-methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-
2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide
342641-91-2P, 5-[6-(4-Ethylphenyl)-2-oxo-1,2-dihydroindol-3-
ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-(pyrrolidin-1-yl)ethyl)amide 342641-92-3P,
5-[6-(2,4-Dimethoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide
342641-93-4P, 5-[6-(3-Isopropylphenyl)-2-oxo-1,2-dihydroindol-3-
ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-(pyrrolidin-1-yl)ethyl)amide 342641-94-5P,
5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-
pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 342641-95-6P
, 3-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-
ylmethylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid
342641-96-7P, 5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-
ylidenemethyl) - 2,4-dimethyl - 1H-pyrrole - 3-carboxylic acid
(2-(pyrrolidin-1-yl)ethyl)amide 342641-97-8P,
5-[5-(3-Chlorophenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide
342641-98-9P, 2,4-Dimethyl-5-[2-oxo-5-(pyridin-3-ylsulfamoyl)-1,2-
dihydroindol-3-ylidenemethyl]-1H-pyrrole-3-carboxylic acid
(2-(pyrrolidin-1-yl)ethyl)amide 342642-01-7P,
5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
342642-02-8P, 5-[5-(3-Chlorophenylsulfamoyl)-2-oxo-1,2-
dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethylaminoethyl)amide 346405-32-1P, 5-(5-Fluoro-2-oxo-1,2-
dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-(pyrrolidin-1-yl)ethyl)amide 356068-82-1P,
5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-
pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide
356068-90-1P, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-
2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
356068-91-2P, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-
ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
356068-92-3P, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-
ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ethyl)amide
356068-95-6P, 2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-
ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide
356068-96-7P, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-
2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide
356068-97-8P, 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-
```

RN

CN

```
ylidenemethyl) -2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-ethylaminoethyl)amide 356068-99-0P, 5-(5-Fluoro-2-oxo-1,2-
dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
(2-diethyl-N-oxoaminoethyl) amide 356069-03-9P,
5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-
pyrrole-3-carboxylic acid [2-(4-methylpiperazin-1-yl)ethyl]amide
356069-04-0P, 5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl) -
2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-methylpiperazin-1-
y1)ethyl]amide 356069-05-1P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-3-
ylidenemethyl) -2,4-dimethyl-1H-pyrrole-3-carboxylic acid
[2-(4-methylpiperazin-1-yl)ethyl]amide 356069-07-3P,
5-(2-0xo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-
carboxylic acid [2-(4-methylpiperazin-1-yl)ethyl]amide
356069-09-5P, 5-(2-0xo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-
dimethyl-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethylpiperazin-1-
yl)ethyl]amide 356069-12-0P, 5-(5-Fluoro-2-oxo-1,2-dihydro-indol-
(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
[2-(3,5-dimethylpiperazin-1-yl)ethyl]amide 356069-13-1P,
5-(5-Chloro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-
pyrrole-3-carboxylic acid [2-(3,5-dimethylpipexazin-1-yl)ethyl]amide
356069-15-3P, 5-(5-Bromo-2-oxo-1,2-dihydroindol-(3Z)-
ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
[2-(3,5-dimethylpiperazin-1-yl)ethyl]amide-468745-38-2P,
5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-
pyrrole-3-carboxylic acid [2-(pyridin-2-yl)ethyl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
   (protein kinase modulator; prepn. of prodrugs of
   (pyrrolylmethylidene) indolinones and activity as modulators of protein
   kinases)
342641-60-5 CAPLUS
1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
ylidene) methyl] -N-[2-(dimethylamino) ethyl] -2,4-dimethyl- (9CI) (CA INDEX
NAME)
```

Br
$$\stackrel{H}{\stackrel{N}{\longrightarrow}} O$$
 $\stackrel{H}{\stackrel{N}{\longrightarrow}} Me$ $\stackrel{C-}{\stackrel{NH-CH_2-CH_2-NMe_2}{\bigcirc}} O$

RN 342641-61-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Ph
$$H$$
 O H Me CH Me $C-NH-CH_2-CH_2-NMe_2$

RN 342641-62-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
 & H \\
 & N \\
 & CH \\
 & Me \\
 & C-NH-CH_2-CH_2-NMe_2 \\
 & | O \\
 & O$$

RN 342641-63-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Br
$$CH \longrightarrow Me$$
 $C-NH-CH_2-CH_2-NEt_2$

RN 342641-64-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-65-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3=(1H-imidazol-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 342641-66-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-67-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-68-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-69-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-70-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA

INDEX NAME)

RN 342641-71-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N=[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-72-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-73-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-74-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[6-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-75-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

10081147

RN 342641-76-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-77-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O & H & Me \\ \hline & N & Me & C-NH-(CH_2)_3-NMe_2 \\ & O & & O \end{array}$$

RN 342641-78-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Ph
$$CH \longrightarrow Me$$
 $C-NH-(CH_2)_3-NMe_2$
 $C-NH-(CH_2)_3-NMe_2$

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-80-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-81-0 CAPLUS

CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[4-[[[3-(diethylamino)propyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-(9CI) (CA INDEX NAME)

RN 342641-82-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Br
$$CH \longrightarrow Me$$
 $CH \longrightarrow Me$ $C-NH-(CH2)3-NEt2$

RN 342641-83-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

RN 342641-84-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

RN 342641-85-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-bis(1-methylethyl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

10081147

RN 342641-87-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

RN 342641-88-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-butylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-89-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1-2-dihydro-6-[2-methoxy-5-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-91-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-ethylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-92-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[-[6-(-2-4-dimethoxyphenyl)-1-72-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)

(CA INDEX NAME)

RN 342641-93-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[3-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-(9CI) (CA INDEX NAME)

RN 342641-94-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-4-dimethyl-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O & H & Me \\ \hline & CH & N & Me \\ \hline & C-NH-CH_2-CH_2-NEt_2 \\ & 0 & \\ \end{array}$$

RN 342641-95-6 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

$$HO_2C$$
 H
 N
 O
 H
 N
 Me
 $C-NH-CH_2-CH_2-NEt_2$
 O

RN 342641-96-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-(9CI) (CA INDEX NAME)

RN 342641-97-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-98-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-[(3-pyridinylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342642-01-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4dimethyl- (9CI) (CA INDEX NAME)

RN 342642-02-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 346405-32-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356068-82-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356068-90-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 356068-91-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 356068-92-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-(9CI) (CA INDEX NAME)

RN 356068-95-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 356068-96-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$^{\text{H}}_{\text{N}}$$
 $^{\text{O}}_{\text{CH}}$ $^{\text{H}}_{\text{N}}$ $^{\text{Me}}_{\text{Me}}$ $^{\text{C-}}_{\text{NH-CH}_2-\text{CH}_2-\text{NMe}_2}$

RN 356068-97-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356068-99-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethyloxidoamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-03-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356069-04-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI)

(CA INDEX NAME)

RN 356069-05-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356069-07-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356069-09-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 356069-12-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-(9CI)
(CA_INDEX_NAME)

Double bond geometry as shown.

RN 356069-13-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 356069-15-3 CAPLUS

Double bond geometry as shown.

RN 468745-38-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

REFERENCE COUNT:

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 10 CAPLUS COPYRIGHT 2002 ACS 2002:658111 CAPLUS

3

ACCESSION NUMBER: DOCUMENT NUMBER:

_137::185408_____

TITLE:

3-(4-Amidopyrrol-2-ylmethylidene)-2-indolinone

derivatives as protein kinase inhibitors

INVENTOR(S):

Guan, Huiping; Liang, Congxin; Sun, Li; Tang, Peng Cho; Wei, Chung Chen; Mauragis, Michael A.; Vojkovsky,

Tomas; Jin, Qingwu; Herrinton, Paul Matthew

PATENT ASSIGNEE(S):

SOURCE:

GI

PCT Int. Appl., 167 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	PATENT NO. KI					DATE			A	PPLI	CATI	ON NO	ο.	DATE			
WO	2002066463			A:	1	2002	0829		WO 2002-US4407				7	20020215			
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,
		UA,	ŪĠ,	US,	UZ,	VN,	ΥU,	ZA,	ZM,	ZW,	AM,	ΑZ,	BY,	KG,	ΚZ,	MD,	RU,
		TJ,	TM														
	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	ŬĠ,	ZM,	ZW,	AT,	BE,	CH,
		CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,
		BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG
PRIORITY APPLN. INFO.:								1	US 20	001-	2686	83P	P	20010	215		
					1	US 20	001-	3123	61P	P	20010	815					
OTHER SOURCE(S):						MARPAT 137:185408											

Title compds. I [R1 = H, halo, alkyl, haloalkoxy, cycloalkyl, heterocyclic, OH, alkoxy, (un)esterified CO2H, (un)substituted NH2, CONH2; R2 = H, halo, alkyl, trihalomethyl, OH, alkoxy, CN, (un)substituted NH2, SO2NH2, (un)esterified CO2H, SO2R8, R8 = alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl; R3-R6 = H, alkyl; R7 = H, alkyl, aryl, heteroaryl, acyl; Z = aryl, heteroaryl, heterocyclic, (un)substituted NH2] were prepd. for use as protein kinase inhibitors in treatment of diseases, such as cancer (no data). Thus, Et 3,5-dimethyl-4-pyrrolecarboxylate was oxidized to the 5-carboxaldehyde, followed by ester hydrolysis, reaction with 5-fluoro-2-oxindole and amidation to give the amide II.

II

IT 375798-55-3P 452104-42-6P 452104-43-7P 452104-44-8P 452104-45-9P 452104-46-0P 452104-47-1P 452104-48-2P 452104-49-3P 452104-50-6P 452104-62-0P 452104-63-1P 452104-64-2P 452104-65-3P 452104-66-4P 452104-67-5P 452104-68-6P 452104-69-7P 452104-70-0P 452104-71-1P 452104-72-2P 452104-73-3P 452104-74-4P 452104-75-5P 452104-76-6P 452104-77-7P 452104-78-8P 452104-79-9P 452104-80-2P 452104-81-3P 452104-82-4P 452104-83-5P 452104-84-6P 452104-85-7P 452104-86-8P 452104-87-9P 452104-88-0P 452104-89-1P 452104-90-4P 452104-91-5P 452104-92-6P 452105-04-3P 452105-05-4P 452105-06-5P 452105-07-6P 452105-08-7P 452105-09-8P 452105-10-1P 452105-11-2P 452105-12-3P 452105-13-4P 452105-14-5P 452105-15-6P 452105-16-7P 452105-17-8P 452105-18-9P 452105-19-0P 452105-20-3P 452105-21-4P 452105-22-5P 452105-23-6P 452105-24-7P 452105-25-8P 452105-26-9P 452105-27-0P 452105-28-1P 452105-29-2P 452105-30-5P 452105-31-6P 452105-32-7P 452105-44-1P 452105-45-2P 452105-46-3P 452105-47-4P 452105-62-3P

10081147

452105-63-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivs. as protein kinase inhibitors)

RN 375798-55-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$\begin{array}{c|c} & & & \\ &$$

RN 452104-42-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-43-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-44-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-45-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-46-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-47-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-48-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 452104-49-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 452104-50-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 452104-62-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 452104-63-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 452104-64-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-65-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 452104-66-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 452104-67-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-68-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-69-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-70-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[3-(2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$F_3C-0$$

H
N

 CH
 CH
 CH_2
 CH

RN 452104-71-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

452104-72-2 CAPLUS

RN

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$F_3C-0$$
 H
 N
 CH
 N
 Me
 CH_2
 $CH-OH$
 CH_2
 CH_2

RN 452104-73-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-74-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-75-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-76-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-77-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-78-8 CAPLUS

CN lH-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-N,2,4-trimethyl-(9CI) (CA INDEX NAME)

10081147

RN 452104-79-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 452104-80-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 452104-81-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452104-82-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

452104-83-5 CAPLUS RN

1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME) CN

RN 452104-84-6 CAPLUS

CN

1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$F_3C-O$$
 CH
 NH
 CH_2
 $CH-OH$
 CH_2
 O

RN 452104-85-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 452104-86-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 452104-87-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 452104-88-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 452104-89-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 452104-90-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 452104-91-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double_bond_geometry_as_shown.-

$$\begin{array}{c|c} & & & \\ &$$

RN 452104-92-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 452105-04-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 452105-05-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 452105-06-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$F_3C \underbrace{ \begin{array}{c} H \\ N \\ N \end{array} }_{N} \underbrace{ \begin{array}{c} Me \\ N \\ H \end{array} }_{N} \underbrace{ \begin{array}{c} N \\ N \\ N \end{array} }_{N} \underbrace{ \begin{array}{c} N$$

RN 452105-07-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 452105-09-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 452105-10-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

RN 452105-11-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-hydroxypropyl]-2,4-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

RN 452105-12-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-hydroxypropyl]-2,4-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

RN 452105-13-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 452105-14-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 452105-15-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[(2R)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 452105-16-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 452105-17-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[(2S)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 452105-18-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 452105-19-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 452105-20-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452105-21-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 452105-22-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

-Double bond-geometry-as shown-

RN 452105-23-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 452105-24-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 452105-25-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 452105-26-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

$$\begin{array}{c|c} & & & \\ &$$

RN 452105-27-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} F & H & Me \\ \hline N & O & H & OH \\ \hline N & Me & OH & N \\ \hline N & N & N \\ \hline \end{array}$$

10081147

RN 452105-28-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 452105-29-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-B

RN 452105-30-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-

ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 452105-31-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 452105-32-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 452105-44-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 452105-45-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 452105-46-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 452105-47-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

RN 452105-62-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-N,2,4-trimethyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

RN 452105-63-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-N,2,4-trimethyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

2002:539677 CAPLUS

DOCUMENT NUMBER:

137:109202

TITLE:

Preparation of 4-aryl substituted indolinones as

protein kinase signal transduction modulators for

inhibiting abnormal cell proliferation

INVENTOR(S):

Cui, Jingrong; Zhang, Ruofei; Shen, Hong; Chu, Ji Yu;

Zhang, Fang-Jie; Koenig, Marcel; Do, Steven Huy; Li,

Xiaoyuan; Wei, Chung-Chen; Tang, Peng Cho

PATENT ASSIGNEE(S):

USA

SOURCE:

PCT Int. Appl., 560 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. K				KI	ND :	DATE			APPLICATION NO.					DATE				
WO	WO 2002055517			A2		20020718			WO 2001-US4856					34 20011220				
WO	2002055517			A	A3 200		20926											
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,	
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	KZ,	LC,	LK,	LR,	
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,	
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,	
		UA,	UG,	US,	UΖ,	VN,	YU,	ZA,	ZM,	ZW,	AM,	AZ,	BY,	KG,	ΚZ,	MD,	RU,	
		TJ,	TM															
	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	ŪĠ,	ZM,	ZW,	AT,	BE,	CH,	
		CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	
		BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG	
PRIORITY APPLN. INFO.:								1	US 2	000-	2564	79P	P	2000	1220			
OTHER SOURCE(S):					MARPAT 137:109202													
GI																		

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = (un)substituted aryl or heteroaryl; R2 = H, halo, alkyl, alkenyl, alkynyl, heterocyclyl, etc.; R3 = (un)substituted pyrrole or cycloalkenylpyrrole], as well as pharmaceutical compns. thereof, are prepd. and disclosed as compds. capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Thus II, was prepd. via condensation of 4-phenyl-1,3-dihydroindol-2-one with 5-formyl-2-methyl-4-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-3-carboxylic acid Et ester. I

```
were evaluated against eight specfic kinases, e.g., FGFR1, for which I
    possessed IC50 values (.mu.M) of 0.0091-2.07. The present invention also
    relates to methods for treating protein kinase related disorders.
     442558-05-6P 442558-07-8P 442558-08-9P
     442558-09-0P 442558-15-8P 442558-16-9P
     442558-17-0P 442558-23-8P 442558-24-9P
     442558-25-0P 442558-31-8P 442558-32-9P
     442558-33-0P 442558-39-6P 442558-40-9P
     442558-41-0P 442558-48-7P 442558-49-8P
     442558-50-1P 442558-54-5P 442558-56-7P
     442558-57-8P 442558-58-9P 442558-62-5P
     442558-63-6P 442558-65-8P 442558-66-9P
     442558-67-0P 442558-71-6P 442558-88-5P
     442558-89-6P 442558-90-9P 442558-91-0P
     442558-92-1P 442558-93-2P 442558-94-3P
     442558-96-5P 442558-97-6P 442558-98-7P
     442559-03-7P 442559-05-9P 442559-07-1P
     442559-08-2P 442559-09-3P 442559-14-0P
     442559-19-5P 442559-20-8P 442559-42-4P
     442559-43-5P 442559-53-7P 442559-54-8P
     442559-55-9P 442559-57-1P 442559-79-7P
     442559-80-0P 442559-97-9P 442559-98-0P
    442559-99-1P 442560-00-1P 442560-01-2P
     442560-02-3P 442560-03-4P 442560-04-5P
     442560-07-8P 442560-09-0P 442560-10-3P
     442560-11-4P 442560-14-7P 442560-22-7P
     442560-25-0P 442560-26-1P 442560-27-2P
     442560-29-4P 442560-39-6P 442560-43-2P
     442560-44-3P 442560-51-2P 442560-69-2P
     442560-79-4P 442560-80-7P 442560-81-8P
     442560-83-0P 442560-88-5P 442561-01-5P
     442561-06-0P 442561-07-1P 442561-11-7P
     442561-12-8P 442561-13-9P 442561-39-9P
     442561-48-0P 442561-52-6P 442561-53-7P
     442561-54-8P 442561-55-9P 442561-56-0P
     442561-76-4P 442561-77-5P
    RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (target compd.; prepn. of (aryl) (pyrrolylmethylene) indolinones as
        protein kinase signal transduction modulators)
RN
     442558-05-6 CAPLUS
    1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-
CN
     4-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)
      Н
 Ph
                       -NH-CH_2-CH_2-NEt_2
```

RN 442558-07-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[4-(4-fluorophenyl)1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA
INDEX NAME)

RN 442558-08-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442558-09-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]-(9CI) (CA INDEX NAME)

RN 442558-15-8 CAPLUS
CN-1H-Pyrrole-3-carboxamide,-N-{2-(diethylamino)ethyl]=5=[-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

•

RN 442558-16-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442558-17-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3Hindol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl](9CI) (CA INDEX NAME)

RN 442558-23-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CAINDEX NAME)

10081147

RN 442558-24-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442558-25-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]-(9CI) (CA INDEX NAME)

RN 442558-31-8 CAPLUS

_CN __1H-Pyrrole=3-carboxamide, 5-[[4-(3-chlorophenyl)-1,2-dihydro=2-oxo=3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CAINDEX NAME)

RN 442558-32-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442558-33-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3Hindol_3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2-3-triazol=1-yl)ethyl]-(9CI) (CA INDEX NAME)

RN 442558-39-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 442558-40-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442558-41-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]-(9CI) (CA INDEX NAME)

RN 442558-48-7 CAPLUS

-CN -1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 442558-49-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442558-50-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(-1H-1,-2,-3-triazol-1-yl)ethyl]-(9CI) (CA INDEX NAME)

RN 442558-54-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-5-[[1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O & H & Me \\ \hline & CH & Me & C-NH-CH_2-CH_2-N(Pr-i)_2 \\ \hline & & & & & \\ MeO & & & & & \\ \end{array}$$

$$\begin{array}{c|c} H & O & H & Me \\ \hline & CH & Me & C-NH-CH_2-CH_2-N(Pr-i)_2 \\ \hline & & & & & \\ MeO & & & & & \\ \end{array}$$

RN 442558-56-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 442558-57-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442558-58-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

RN 442558-62-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[bis (1-methylethyl-) amino] ethyl]=5=[[4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 442558-63-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & H & O & H & \\ \hline & N & O & H & \\ \hline & CH & N & \\ \hline & Me & C-NH-CH_2-CH_2-NEt_2 \\ \hline & O & \\ \hline & O & \\ \end{array}$$

RN 442558-65-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX

NAME)

RN 442558-66-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442558-67-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

RN 442558-71-6 CAPLUS

CN__1H_Pyrrole=3-carboxamide,-N-[2-[bis(1-methylethyl)amino]ethyl]-5-[[4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O & H & Me \\ \hline CH & N & Me & C-NH-CH_2-CH_2-N(Pr-i)_2 \\ \hline Br & O & \end{array}$$

RN 442558-88-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

RN 442558-89-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

RN 442558-90-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

RN 442558-91-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

RN 442558-92-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-bromophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & H & O & H & \\ \hline & H & N & \\ \hline & CH & N & \\ \hline & Me & C-NH-CH_2-CH_2-NEt_2 \\ \hline & & O & \\ \hline & & O & \\ \hline \end{array}$$

RN 442558-93-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-4-(4-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

RN 442558-94-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-4-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

RN 442558-96-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O & H & Me \\ \hline CH & N & Me & C-NH-CH_2-CH_2-NEt_2 \\ \hline 0 & O & \\ \end{array}$$

RN 442558-97-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442558-98-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]-(9CI) (CA INDEX NAME)

RN 442559-03-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]=5=[[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 442559-05-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

$$\begin{array}{c} H \\ N \\ O \\ CH \\ Me \\ C-NH-(CH_2)_3-NEt_2 \\ \parallel \\ O \\ \end{array}$$

RN 442559-07-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O & H & Me \\ \hline CH & N & Me & C-NH-CH_2-CH_2-NEt_2 \\ \hline \\ F_3C & O & \end{array}$$

RN 442559-08-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442559-09-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

RN 442559-14-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide,-N-[3-(diethylamino)propyl]-5-[[1,2-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

$$H$$
 O
 H
 N
 Me
 $C-NH-(CH2)3-NEt2
 $O$$

RN 442559-19-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chloro-4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(3-chloro-4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

RN 442559-42-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-[4-(trifluoromethoxy)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 442559-43-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-[4-(trifluoromethoxy)phenyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

RN 442559-53-7 CAPLUS

CN 1H-Pyrrole=3-carboxamide-N-[3-(diethylamino)propyl]-5-[(Z)-[4-(4-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI)

(CA INDEX NAME)

Double bond geometry as shown.

RN 442559-54-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

RN 442559-55-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N,2,4-trimethyl-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442559-57-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 442559-79-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-4-[3-(2-hydroxyethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442559-80-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-4-[3-(2-hydroxyethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442559-97-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442559-98-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[3-(2-methyl-1-piperidinyl)propyl](9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$\begin{array}{c|c} & & & \\ &$$

RN 442559-99-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442560-01-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442560-02-3 CAPLUS
CN 1H-Pyrrole=3-carboxamide,-5-[-(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.

$$\begin{array}{c|c} H & O & Me \\ \hline N & N & M \\ \hline Z & N & M \\ \hline N & M & M \\ \end{array}$$

RN 442560-03-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-4-methyl-(9CI) (CA INDEX NAME)

RN 442560-04-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442560-07-8 CAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442560-09-0 CAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-

indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-piperidinyl)ethyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.

RN 442560-10-3 CAPLUS
CN 1H_Pyrrole_3_acetamide, 5--[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3Hindol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA
INDEX NAME)

Double bond geometry as shown.

RN 442560-11-4 CAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442560-14-7 CAPLUS

CN 1H-Pyrrole-3-acetamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442560-22-7 CAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(2H-1,2,3-triazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 442560-25-0 CAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2 oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442560-26-1 CAPLUS

CN 1H-Pyrrole-3-acetamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 442560-27-2 CAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double_bond_geometry_as_shown.

RN 442560-29-4 CAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442560-39-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(4-[1,1'-biphenyl]-3-yl-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-1,2,3-triazol-2-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

- Double-bond-geometry-as-shown-

RN 442560-43-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442560-51-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3,5-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442560-69-2 CAPLUS

CN = 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[4-[3-[2-(dimethylamino)-2-oxoethyl]phenyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442560-79-4 CAPLUS

CN lH-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)methyl]- (9CI) (CA INDEX NAME)

RN 442560-80-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-amino-1H-indazol-5-yl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$H_{2}N$$
 $H_{2}N$
 $H_{3}N$
 $H_{4}N$
 $H_{5}N$
 H

RN 442560-81-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-amino-1H-indazol-5-yl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-(9CI) (CA INDEX NAME)

$$\begin{array}{c} H_{2N} \\ N \\ N \\ N \\ H \end{array}$$

RN 442560-83-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442560-88-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2,4-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442561-01-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442561-06-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(4-acetyl-1-piperazinyl)ethyl]-5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442561-11-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-4-methyl-(9CI) (CA INDEX NAME)

RN 442561-12-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-4-methyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442561-13-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442561-39-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-4-[3-(2-hydroxyethoxy)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-

(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442561-48-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442561-52-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-4-[3-[(methylamino)carbonyl]phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 442561-53-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidenelmethyl]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-2,4-

indol-3-ylidene]methyl]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-2,4dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442561-54-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-5[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4methyl- (9CI) (CA INDEX NAME)

RN 442561-55-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442561-56-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-2-fluoro-4-methyl- (9CI) (CA INDEX NAME)

RN 442561-76-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 442561-77-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-4-methyl- (9CI) (CA INDEX NAME)

ANSWER 4 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

2002:31440 CAPLUS

DOCUMENT NUMBER:

136:102386

TITLE:

Preparation and use of 4-heteroaryl-3-heteroarylidenyl-

2-indolinones and their use as protein kinase

inhibitors

INVENTOR(S): ------Tang, -Peng-Cho; Wei, Chung Chen; Huang, Ping; Cui,

Jingron

PATENT ASSIGNEE(S):

Sugen, Inc., USA

SOURCE:

PCT Int. Appl., 164 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.				KIND		DATE			APPLICATION NO.						DATE			
									-		- - - -							
WO	√O 2002002551			A1		20020110			WO 2001-US20768 20010629									
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,	
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	ΕE,	ES,	FI,	GB,	GD,	GE,	GH,	
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PL,	PT,	
		RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,	UG,	US,	
		UZ,	VN,	YU,	ZA,	ZW,	AM,	AZ,	BY,	KG,	KZ,	MD,	RU,	ТJ,	TM			
	RW:	GH,	GM,	KE,	LS,	MW,	ΜZ,	SD,	SL,	SZ,	TZ,	UG,	ZW,	AT,	BE,	CH,	CY,	
		DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,	
		ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	TG			
AU 2001070260					A5 20020114				AU 2001-70260					20010629				
PRIORITY APPLN. INFO.				. :					US 2000-215654P				P	20000	0630			
					1	70 2	001-1	US20'	768	W	2001	0629						
OTHER C	MADDAT 126.102286																	

OTHER SOURCE(S):

MARPAT 136:102386

GI

ΙΙ

Title compds. I [R1-2 = H, alkyl, cycloalkyl, aryl, heteroaryl, AB heteroalicyclic, halo, etc.; Het = (un) substituted arom. heterocycle contq. at least one and not more than two N atoms, tetrahydro(thio)pyranyl, (thio)morpholino, piperidinyl, piperazinyl, tetrazolyl, etc.; Q = (un)substituted arom. heterocycle contg. not more than two N atoms, 5-membered ring (un)substituted heterocycle contg. N, O or S, e.g., imidazolyl, pyrrolyl, indolyl, etc.] with some exceptions, were prepd. Included are 75 synthetic examples and results for several protein tyrosine kinase assays for those compds. For instance, 4-bromoindole was coupled to bis (pinacolato) diborane (DMSO, KOAC, PdCl2(dppf).bul.CH2Cl2, 80.degree.C, 22 h). The resulting dioxaborolane was coupled to 4-bromopyridine.bul.HCl (THF, Pd(PPh3)4, NaOH, 70.degree.C, 6 h) to give the indole which was treated with C5H5N.bul.Br3 (t-BuOH/EtOH/H2O, 1h) followed by zinc (stirred 1 addnl. hour) to give 4-(pyridin-4-yl)-1,3-dyhydroindol-2-one as a yellow solid. Condensation of this intermediate with 5-methylimidazole-4-carboxaldehyde (EtOH, piperidine, 2 days) afforded II. II had IC50 = 4.88 mM for FGFR-1 tyrosine kinase and 0.03 mM for cdk2/cyclin A tyrosine kinase. I are useful in treating cancer, immunol. disorders, etc.

IT 388116-64-1P 388116-99-2P 388117-08-6P 388117-10-0P 388117-12-2P 388117-28-0P 388117-30-4P

Ι

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; prepn. and use of 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors)

RN 388116-64-1 CAPLUS

CN

1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(4-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 388116-99-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 388117-08-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

RN 388117-10-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

RN 388117-12-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-4-(4-piperidinyl)-3H-indol-3-ylidene]methyl]-4-methyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

RN 388117-28-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[4-(2-amino-5-pyrimidinyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 388117-30-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-4-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

REFERENCE COUNT:

9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2001:868415 CAPLUS

DOCUMENT NUMBER:

136:697

TITLE:

Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives

INVENTOR(S): Moon, Malcolm Wilson; Morozowich, Walter; Gao, Ping;

Tang, Peng Cho

Sugen, Inc., USA; Pharmacia & Upjohn Company PATENT ASSIGNEE(S):

SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.				KIND		DATE		APPLICATION NO. DATE									
		2001090068								WO 2001-US16757 200105								
	WO	2001090068		A3		20020606												
		W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
			CO.	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
			•	,	•	•		•		•	•	•		•	KZ,		•	•
				•	•	•	•			•		•		•	NO,	•	•	•
											•				TZ,			
										•	•	-			TJ,		00,	05,
		D.1.1									•	_			-		OTT	037
		RW:	•	•							•		•		AT,		•	•
			DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	ΝL,	PT,	SE,	TR,	BF,
			_BJ.,-	- CF₌, ·	-CG ,-	-CI-,	-CM;-	-GA-,	GN,	-GW,	ML,	MR,	NE;	SN,	TD,	TG"	2200 11 2.20	
	US	2002	0322	04	A:	1	2002	0314		U	S 20	01-8	63804	4	2001	0524		
	US	2002035140			A1 200203		0321		US 2001-863905			5	20010524					
	US	6451	838		B	2	2002	0917										
	US	2002	0378	78	A	1	2002	0328		U	S 20	01-86	53819	9	20010	0524		
		6482					2002											
PRIOR						_	2002		т	TC 21	000-	2070	מחר	D	20000	1524		
FKIOK	1 1	. AFF	DTA	INFO	• •									_				
									,	JS 21	000-	22504	± 3 P	P	20000	POTT		

OTHER SOURCE(S): MARPAT 136:697

The present invention is directed to Mannich base prodrugs of certain 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs. that modulate the activity of protein kinases ("PKs"). Pharmaceutical compns. comprising these compds., methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compns. comprising these compds. and methods of prepg. them are also disclosed.

IT 326914-13-0P

> RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs.)

RN 326914-13-0 CAPLUS

1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-CN dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

IT 375798-55-3P

RL: SPN (Synthetic preparation); PREP (Preparation) (Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs.)

375798-55-3 CAPLUS RN

1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-(5-CN fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$\begin{array}{c|c} & & & \\ &$$

ANSWER 6 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

2001:617993 CAPLUS

DOCUMENT NUMBER:

135:195497

TITLE: Preparation of pyrrole substituted 2-indolinone

protein kinase inhibitors for treatment of cancer

INVENTOR(S):

Tang, Peng Cho; Miller, Todd; Li, Xiaoyuan; Sun, Li; Wei, Chung Chen; Shirazian, Shahrzad; Liang, Congxin;

Vojkovsky, Tomas; Nematalla, Asaad S.

PATENT ASSIGNEE(S):

Sugen, Inc., USA

SOURCE:

PCT Int. Appl., 225 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO. DATE
WO 2001060814 WO 2001060814	A2 2001	L0823 WO 2001-US4813 20010215
W: AE, AG,	AL, AM, AT,	AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
		JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
•		SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, BY, KG, KZ, MD, RU, TJ, TM
· · · · · · · · · · · · · · · · · · ·	• •	MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF,	CG, CI, CM,	GA, GN, GW, ML, MR, NE, SN, TD, TG
		EP 2001-914376 20010215
· · · · · · · · · · · · · · · · · · ·		ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO).:	US 2000-182710P P 20000215 US 2000-216422P P 20000706
		US 2000-243532P P 20001027 WO 2001-US4813 W 20010215
OTHER SOURCE(S):	MARPAT :	

GI

$$R^2$$
 R^3
 R^4
 R^7
 R^6
 R^7
 R^6
 R^7
 R^6
 R^7
 R^6

The title compds. (I) [wherein R1 = H, halo, (cyclo)alkyl, (hetero)aryl, AB heteroalicyclic, OH, alkoxy, acyl, (un) substituted amino or carbamoyl, etc.; R2 = H, halo, alkyl, trihalomethyl, OH, alkoxy, CN, (hetero)aryl, (un) substituted amino, acyl(amino), or sulfamoyl, etc.; R3 = H, halo, alkyl, trihalomethyl, OH, alkoxy, (hetero)aryl, (un)substituted acyl, (acyl)amino, sulfamoyl, or alkylsulfonyl, etc.; R4 = H, halo, alkyl, OH, alkoxy, or (un) substituted amino; R5 and R6 = independently H, alkyl, or acyl; R7 = H, alkyl, (hetero)aryl, or acyl; and their pharmaceutically acceptable salts] were prepd. as protein kinase modulators for the treatment of cellular disorders such as cancer. For example, 5-fluoro-1,3-dihydroindol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide to give II (55%). II exhibited comparable activity against Flk-1 and PDGFR.beta. and inhibited PDGF-dependent receptor phosphorylation in cells with an IC50 value of approx. 0.03 .mu.M. In efficacy expts. against various cancers in mice, II was well tolerated at 80 mg/kg/day, even when dosed continuously for more than 100 days.

II

Ι

IT 326914-13-0P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrrole substituted 2-indolinone protein kinase inhibitors by condensation of dihydroindolones with formylpyrroles for treatment of cancer and other diseases)

RN 326914-13-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

```
NEt<sub>2</sub>
                               Me
     326914-09-4P 326914-10-7P 326914-17-4P
IT
     326914-19-6P 342641-60-5P 342641-61-6P
     342641-62-7P 342641-63-8P 342641-64-9P
     342641-65-0P 342641-66-1P 342641-67-2P
     342641-68-3P 342641-69-4P 342641-70-7P
     342641-71-8P 342641-72-9P 342641-73-0P
     342641-74-1P 342641-75-2P 342641-76-3P
     342641-77-4P 342641-78-5P 342641-79-6P
     342641-80-9P 342641-81-0P 342641-82-1P
     342641-83-2P 342641-84-3P 342641-85-4P
     342641-87-6P 342641-88-7P 342641-89-8P
     342641-91-2P 342641-92-3P 342641-93-4P
     342641-94-5P_342641-95-6P-342641-96-7P
     342641-97-8P 342641-98-9P 342642-01-7P
     342642-02-8P 342642-09-5P 342642-10-8P
     342642-11-9P 346405-32-1P 356068-82-1P
     356068-90-1P 356068-91-2P 356068-92-3P
     356068-94-5P 356068-95-6P 356068-96-7P
     356068-97-8P 356068-99-0P 356069-03-9P
     356069-04-0P 356069-05-1P 356069-07-3P
     356069-09-5P 356069-12-0P 356069-13-1P
     356069-15-3P 356069-16-4P 356069-17-5P
     356069-18-6P 356069-19-7P 356069-20-0P
     356069-21-1P 356069-22-2P 356069-23-3P
     356069-24-4P 356069-25-5P 356069-26-6P
     356069-27-7P 356069-28-8P 356069-29-9P
     356069-30-2P 356069-31-3P 356069-33-5P
     356069-34-6P 356069-35-7P 356069-36-8P
     356069-37-9P 356069-38-0P 356069-39-1P
     356069-40-4P 356069-41-5P 356069-42-6P
     356069-43-7P 356069-44-8P 356069-45-9P
     356069-46-0P 356069-47-1P 356069-48-2P
     356069-49-3P 356069-50-6P 356069-51-7P
     356069-53-9P 356069-55-1P 356069-57-3P
     356069-58-4P 356069-59-5P 356069-60-8P
     356069-61-9P 356069-62-0P 356069-64-2P
     356069-65-3P 356069-66-4P 356069-67-5P
     356069-68-6P 356069-69-7P 356069-70-0P
     356069-71-1P 356069-72-2P 356069-73-3P
     356069-74-4P 356069-75-5P 356069-76-6P
     356069-77-7P
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); USES (Uses)
        (prepn. of pyrrole substituted 2-indolinone protein kinase inhibitors
        by condensation of dihydroindolones with formylpyrroles for treatment
        of cancer and other diseases)
RN
     326914-09-4 CAPLUS
CN
     1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(1,2-dihydro-2-
     oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)
```

RN 326914-10-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 326914-17-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 326914-19-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & H & O & Me \\ \hline & N & Me \\ \hline & N & Me \\ \hline & Me \\ & H & \\ \end{array}$$

RN 342641-60-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & H & O & H & Me \\ \hline & CH & Me & C-NH-CH_2-CH_2-NMe_2 \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ &$$

RN 342641-61-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} Ph & H & O & H & Me \\ \hline & & & & \\ & & & & \\ Me & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ \end{array}$$

RN 342641-62-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\$$

RN 342641-63-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Br
$$\stackrel{H}{\longrightarrow}$$
 $\stackrel{O}{\longrightarrow}$ $\stackrel{H}{\longrightarrow}$ $\stackrel{Me}{\longrightarrow}$ $\stackrel{C-NH-CH_2-CH_2-NEt_2}{\bigcirc}$

RN 342641-64-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-65-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-67-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

MeO
$$\stackrel{\text{H}}{\underset{\text{N}}{\bigvee}}$$
 $\stackrel{\text{O}}{\underset{\text{N}}{\bigvee}}$ $\stackrel{\text{H}}{\underset{\text{N}}{\bigvee}}$ $\stackrel{\text{Me}}{\underset{\text{O}}{\bigvee}}$ $\stackrel{\text{C-}}{\underset{\text{NH-}}{\bigvee}}$ $\stackrel{\text{CH}}{\underset{\text{C}}{\bigvee}}$ $\stackrel{\text{CH}}{\underset{\text{NH-}}{\bigvee}}$ $\stackrel{\text$

RN 342641-68-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ \text{Ph} & & \\ & & & \\ \text{Ph} & & \\ & & \\ \text{Me} & & \\ & &$$

RN 342641-69-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-70-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3=(1H-imidazol-1-yl)propyl-]-2,4-dimethyl--(9CI)--(CA-INDEX NAME)

RN 342641-71-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Ph
$$\stackrel{H}{\stackrel{N}{\stackrel{}}}$$
 O $\stackrel{H}{\stackrel{}}$ Me $\stackrel{C-NH-CH_2-CH_2-NEt_2}{\stackrel{\parallel}{\stackrel{}}}$ O

RN 342641-72-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-

ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-73-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-74-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[6-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

C1

$$H$$
 CH
 Me
 $C-NH-CH_2-CH_2-NEt_2$
 O

RN 342641-75-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-76-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-77-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O & H \\ N & Me & \\ C-NH-(CH_2)_3-NMe_2 \\ O & \\ \end{array}$$

RN 342641-78-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-79-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-80-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-81-0 CAPLUS

CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[4-[[[3-(diethylamino)propyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-(9CI) (CA INDEX NAME)

C1 OMe
$$\frac{H}{N}$$
 O H Me $C-NH-(CH2)3-NEt2 O $O$$

RN 342641-82-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Br
$$\stackrel{H}{\sim}$$
 $\stackrel{O}{\sim}$ $\stackrel{H}{\sim}$ $\stackrel{Me}{\sim}$ $\stackrel{C-NH-(CH_2)_3-NEt_2}{\mid}$

RN 342641-83-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

Br
$$O$$
 H N $Pr-i$ $C-NH-CH_2-CH_2-NEt_2$

RN 342641-84-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

RN 342641-85-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-bis(1-methylethyl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

RN 342641-87-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

RN 342641-88-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-butylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA

INDEX NAME)

RN 342641-89-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[2-methoxy-5-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-91-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-ethylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-92-3 CAPLUS

_CN __1H_Pyrrole=3=carboxamide,-5-[[6-(2-4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H= indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-93-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[3-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-(9CI) (CA INDEX NAME)

RN 342641-94-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2=oxo-3H-indol-3-ylidene)methyl]-2-4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O & H & Me \\ \hline & CH & N & Me \\ & & C-NH-CH_2-CH_2-NEt_2 \\ & & & \\ & & O \end{array}$$

RN 342641-95-6 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

$$HO_2C$$
 H
 N
 O
 H
 N
 Me
 $C-NH-CH_2-CH_2-NEt_2$

RN 342641-96-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-(9CI) (CA INDEX NAME)

RN 342641-97-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[(3-chlorophenyl)amino]sulfonyl]-1,2__dihydro-2-oxo=3H=indol=3-ylidene]methyl-1-2,4-dimethyl-N-[2=(1=
__pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-98-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-[(3-pyridinylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342642-01-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4dimethyl- (9CI) (CA INDEX NAME)

RN 342642-02-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342642-09-5 CAPLUS

CN Glycine, N-[[5-[[1,2-dihydro-4-methyl-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

MeNH-S

Me

Me

$$CH$$
 CH
 CH

RN 342642-10-8 CAPLUS

CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 342642-11-9 CAPLUS

CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

RN 346405-32-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356068-82-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]--2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]--(9CI) (CA INDEX NAME)

RN 356068-90-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 356068-91-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 356068-92-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356068-94-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356068-95-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 356068-96-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(dimethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O & H & Me \\ \hline & CH & Me & \\ & & C-NH-CH_2-CH_2-NMe_2 \\ & & & \\ & & & \\ & & & \\ & & & \\ \end{array}$$

RN 356068-97-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 356068-99-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethyloxidoamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-03-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356069-04-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356069-05-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356069-07-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356069-09-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-12-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 356069-13-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-15-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(3,5-dimethyl-1-piperazinyl)ethyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

RN 356069-16-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(ethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O & H & Me \\ \hline & CH & N & Me \\ \hline & C-NH-CH_2-CH_2-NHEt \\ & O & \\ \end{array}$$

RN 356069-17-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethyloxidoamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ &$$

RN 356069-18-6 CAPLUS

CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 356068-82-1 CMF C22 H25 Cl N4 O2

_CM ___ 2_

CRN 97-67-6 CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).

RN 356069-19-7 CAPLUS

CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 342641-94-5 CMF C22 H27 F N4 O2

$$\begin{array}{c|c} H & O & H & Me \\ \hline & CH & N & Me \\ \hline & C-NH-CH_2-CH_2-NEt_2 \\ & 0 & \\ \end{array}$$

CM 2

CRN 97-67-6 CMF C4 H6 O5 Absolute stereochemistry. Rotation (-).

RN 356069-20-0 CAPLUS

CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 356068-90-1 CMF C22 H27 Cl N4 O2

CM 2

CRN 97-67-6 CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).

RN 356069-21-1 CAPLUS

CN Butanedioic acid, hydroxy-, (2S)-, compd. with 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 346405-32-1 CMF C22 H25 F N4 O2

CM 2

CRN 97-67-6 CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).

RN 356069-22-2 CAPLUS

CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(ethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 356069-16-4 CMF C20 H23 F N4 O2

CM 2

CRN 97-67-6 CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).

RN 356069-23-3 CAPLUS

CN Butanedioic acid, hydroxy-, (2S)-, compd. with N-[2-(diethyloxidoamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (9CI) (CA INDEX NAME)

CM 1

CRN 356068-99-0 CMF C22 H27 F N4 O3

Double bond geometry as shown.

CM 2

CRN 97-67-6 CMF C4 H6 O5

Absolute stereochemistry. Rotation (-).

RN 356069-24-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 356069-25-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-26-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-27-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

Br
$$\stackrel{\text{H}}{\overset{\text{N}}}{\overset{\text{N}}{\overset{\text{N}}{\overset{\text{N}}{\overset{\text{N}}{\overset{\text{N}}{\overset{\text{N}}}{\overset{\text{N}}{\overset{\text{N}}{\overset{\text{N}}}{\overset{\text{N}}{\overset{\text{N}}}{\overset{\text{N}}{\overset{\text{N}}}{\overset{\text{N}}{\overset{\text{N}}}{\overset{\text{N}}{\overset{\text{N}}}{\overset{\text{N}}{\overset{\text{N}}}{\overset{\text{N}}{\overset{\text{N}}}{\overset{\text{N}}}{\overset{\text{N}}{\overset{\text{N}}}{\overset{\text{N}}{\overset{\text{N}}}{\overset{\text{N}}{\overset{\text{N}}}{\overset{\text{N}}}{\overset{\text{N}}}{\overset{\text{N}}}{\overset{\text{N}}}{\overset{\text{N}}}{\overset{\text{N}}}{\overset{\text{N}}}}}{\overset{\text{N}}}{\overset{\text{N}}}{\overset{\text{N}}{\overset{\text{N}}{\overset{N}}}{\overset{\text{N}}{\overset{\text{N}}{\overset{N}}}}{\overset{\text{N}}}{\overset{N}}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N}}}{\overset{N}}{\overset{N}}{\overset{N}}{\overset{N$$

RN 356069-28-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ &$$

RN 356069-29-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$\begin{array}{c|c} H & O & Me \\ \hline N & NH \\ \hline N & Me \\ \hline N & Me \\ \hline \end{array}$$

RN 356069-30-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$\begin{array}{c|c} H & O & Me \\ \hline N & N & Me \\ \hline Z & N & Me \\ \hline N & Me \\ \hline N & Me \\ \hline \end{array}$$

RN 356069-31-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)propyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O & Me \\ \hline N & N & H \\ \hline N & Me \\ \hline N & Me \\ \hline N & Me \\ \hline \end{array}$$

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-32-4 CMF C22 H24 Br N5 O3

Double bond geometry as shown.

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 356069-34-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356069-35-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-36-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$\begin{array}{c|c}
H & O & Me \\
NC & & Me \\
NC & & Me \\
NC & & Me
\end{array}$$

$$\begin{array}{c}
H & (CH_2)_3 \\
N & Me
\end{array}$$

RN 356069-37-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356069-38-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double-bond geometry as shown.

RN 356069-39-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356069-40-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-41-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-42-6 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 356069-43-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

_Double_bond_geometry_as_shown.___

RN 356069-44-8 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 356069-45-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[(cyanomethyl)amino]ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double-bond geometry as shown.

RN 356069-46-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-47-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ &$$

RN 356069-48-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-49-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-50-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(hexahydro-2-oxo-1H-azepin-1-yl)propyl]-2,4-dimethyl-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
H & O & Me \\
NC & Me & Me
\end{array}$$

$$\begin{array}{c|c}
H & (CH_2)_3 \\
N & Me
\end{array}$$

10081147

CN 1H-Pyrrole-3-carboxamide, N-[2-(acetylamino)ethyl]-5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-53-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-52-8 CMF C22 H24 F N5 O3

Double bond geometry as shown.

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 356069-55-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-,

mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-54-0 CMF C22 H25 N5 O3

Double bond geometry as shown.

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 356069-57-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-56-2 CMF C23 H24 N6 O3

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 356069-58-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-[(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$\begin{array}{c|c} & H & O & Me & Me \\ \hline & N & Me & Me \\ \hline & N & Me & Me \\ \hline & Me & Me & Me \\ \hline \end{array}$$

RN 356069-59-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-[(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ &$$

RN 356069-60-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[(2-cyanoethyl)amino]ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-61-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[(2-cyanoethyl)amino]ethyl]-5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-62-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-cyano-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-[(2-cyanoethyl)amino]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O & Me \\ \hline N & N & Me \\ \hline \end{array}$$

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 356069-63-1 CMF C22 H24 Cl N5 O3

Double bond geometry as shown.

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 356069-65-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356069-66-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

_Double_bond-geometry-as-shown-

RN 356069-67-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 356069-68-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-methyl]-2,4-dimethyl-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-69-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\$$

RN 356069-70-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$\begin{array}{c|c} H & O & Me \\ \hline N & Me \\ \hline N & Me \\ \hline \end{array}$$

RN 356069-71-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$\begin{array}{c|c} H & \text{Me} \\ \hline N & \text{Me} \\ \hline N & \text{Me} \\ \hline N & \text{Me} \\ \hline \end{array}$$

RN 356069-72-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$\begin{array}{c|c} H & O & Me \\ \hline N & O & Me \\ \hline Z & Me \\ \hline N & Me \\ \hline Me & Me \\ \hline \end{array}$$

RN 356069-73-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-(9CI) (CA INDEX NAME)

RN 356069-74-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-75-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-(9CI) (CA INDEX NAME)

RN 356069-76-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 356069-77-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[[[5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

2001:472477 CAPLUS

DOCUMENT NUMBER:

135:56059

TITLE:

Methods of modulating c-kit tyrosine protein kinase

function with indolinone compounds

INVENTOR(S):

Lipson, Ken; McMahon, Gerald

PATENT ASSIGNEE(S):

Sugen, Inc., USA

SOURCE:

PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.			KIND DATE			APPLICATION NO.			э.	DATE							
										_								
	WO	2001	0456	89	A:	2	2001	0628		W	20	00-U	S350	09	2000	1222		
	WO 2001045689			A3 20020103			0103											
		W:	AE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
			CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,
			HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,
			LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	ΝZ,	PL,	PT,	RO,	RU,
			SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VN,
			YU,	ZA,	ZW,	AM,	AZ,	BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM				
		RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZW,	AT,	BE,	CH,	CY,
			DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,
			ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG		
US 2002010203 A1 20020124 US 2000-741842 20001222																		
EP 1255536					A2 20021113			EP 2000-991704				4	20001222					
		R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
			ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR						
PRIORITY APPLN. INFO.:					. :				1	US 19	999-	1716	93P	P	1999	1222		
									1	WO 2	000-1	US350	009	W	2000	1222		

OTHER SOURCE(S): MARPAT 135:56059

AB The invention concerns indolinone compds. and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity of c-kit kinase.

IT 342641-94-5 346405-32-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(indolinone derivs. for c-kit tyrosine protein kinase function modulation)

10081147

RN 342641-94-5 CAPLUS

1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-CN dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ &$$

346405-32-1 CAPLUS RN

1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-CN ylidene)-methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) NAME)

ANSWER 8 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

2001:396655 CAPLUS

DOCUMENT NUMBER:

135:19549

TITLE:

Preparation of pyrrole substituted 2-indolinones as

antitumor agents

INVENTOR (S):

Shenoy, Narmada; Sorasuchart, Waranush

PATENT ASSIGNEE(S):

Sugen, Inc., USA

SOURCE:

PCT Int. Appl., 249 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE: FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT	NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200	1037820	A2	20010531	WO 2000-US32277	20001122
WO 2001	1037820	ΔZ	20011213		

```
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1233943
                      A2
                                           EP 2000-982228
                                                          20001122
                           20020828
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO.:
                                        US 1999-167544P A1 19991124
                                        WO 2000-US32277 W 20001122
                         MARPAT 135:19549
OTHER SOURCE(S):
GI
```

AB The title compds. [I; R1 = H, alkyl, alkenyl, etc.; R2 = H, halo, alkyl,etc.; R3-R6 = H, alkyl, trihaloalkyl, etc.; R3 and R4, R4 and R5, R5 and R6 may combine to form a six membered aryl ring, OCH2O, OCH2CH2O; R7 = H, alkyl, cycloalkyl, etc.; R8-R10 = H, alkyl, trihaloalkyl, etc.] were prepd. and formulated. E.g., a multi-step synthesis of I [R1-R7 = H; R8, R10 = Me; R9 = (CH2)2CO2H] which showed 79-86% inhibition of tumor growth of Calu-6 cells in mice at 75 and 100 mg/kg/day, was given. The present invention features formulations of indolinones which compds. are ionizable as free acids or free bases. The formulation is suitable for parenteral or oral administration, wherein the formulation comprises an ionizable substituted indolinone, and a pharmaceutically acceptable carrier therefor. The term "ionizable substituted indolinone" includes pyrrole substituted 2-indolinones I which, in addn. to being otherwise optionally substituted on both the pyrrole and 2-indolinone portions of the compd., are necessarily substituted on the pyrrole moiety with one or more hydrocarbon chains which themselves are substituted with at least one polar group.

IT 251356-61-3P 251356-63-5P 251356-64-6P 251356-65-7P 251356-66-8P 251356-67-9P 251356-68-0P 251356-69-1P 251356-70-4P 251356-71-5P 251356-72-6P 251356-73-7P 251356-74-8P 251356-75-9P 251356-76-0P 251356-77-1P 251356-78-2P 342641-60-5P 342641-61-6P 342641-62-7P 342641-63-8P 342641-64-9P 342641-65-0P 342641-66-1P 342641-67-2P 342641-68-3P 342641-72-9P

342641-73-0P 342641-74-1P 342641-75-2P 342641-76-3P 342641-77-4P 342641-78-5P 342641-79-6P 342641-80-9P 342641-81-0P 342641-82-1P 342641-83-2P 342641-84-3P 342641-85-4P 342641-87-6P 342641-88-7P 342641-89-8P 342641-91-2P 342641-92-3P 342641-93-4P 342641-94-5P 342641-95-6P 342641-96-7P 342641-97-8P 342641-98-9P 342642-01-7P 342642-02-8P 342642-09-5P 342642-10-8P 342642-11-9P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of pyrrole substituted 2-indolinones as antitumor agents) 251356-61-3 CAPLUS RN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-CN yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

RN 251356-63-5 CAPLUS

CN 2H-Indol-2-one, 5-bromo-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

Br
$$\stackrel{\text{H}}{\longrightarrow}$$
 $\stackrel{\text{O}}{\longrightarrow}$ $\stackrel{\text{H}}{\longrightarrow}$ $\stackrel{\text{Me}}{\longrightarrow}$ $\stackrel{\text{Me}}{\longrightarrow}$ $\stackrel{\text{CH}_2)}{\longrightarrow}$ $\stackrel{\text{N}}{\longrightarrow}$ $\stackrel{\text{N}}$

RN 251356-64-6 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-phenyl- (9CI) (CA INDEX NAME)

Ph
$$\stackrel{\text{H}}{\sim}$$
 $\stackrel{\text{O}}{\sim}$ $\stackrel{\text{H}}{\sim}$ $\stackrel{\text{Me}}{\sim}$ $\stackrel{\text{Me}}{\sim}$ $\stackrel{\text{CH}}{\sim}$ $\stackrel{\text{CH}}{\sim}$ $\stackrel{\text{N}}{\sim}$ $\stackrel{\text{N}}{\sim$

RN 251356-65-7 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

RN 251356-66-8 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

MeO
$$H$$
 N Me CH N Me Me $(CH2)3-NMe2$

RN 251356-67-9 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

MeO
$$H$$
 N O H Me $(CH2)3-NMe2$

RN 251356-68-0 CAPLUS

CN 2H-Indol-2-one, 5-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

$$C1$$
 H
 CH
 H
 N
 Me
 $CH_2)_3 - NMe_2$

RN 251356-69-1 CAPLUS

CN 2H-Indol-2-one, 6-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

C1

H
N

CH

H
N

Me

(CH2)
$$_3$$

NMe2

RN 251356-70-4 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-methoxy- (9CI) (CA INDEX NAME)

MeO
$$\stackrel{H}{\sim}$$
 $\stackrel{O}{\sim}$ $\stackrel{H}{\sim}$ $\stackrel{Me}{\sim}$ $\stackrel{Me}{\sim}$ $\stackrel{(CH_2)_3-NMe_2}{\sim}$

RN 251356-71-5 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-methoxy- (9CI) (CA INDEX NAME)

MeO
$$\stackrel{H}{\stackrel{N}{\longrightarrow}}$$
 O $\stackrel{H}{\stackrel{N}{\longrightarrow}}$ Me $\stackrel{(CH_2)_3-NMe_2}{\longrightarrow}$

RN 251356-72-6 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-methyl- (9CI) (CA INDEX NAME)

Me
$$CH \longrightarrow Me$$

Me $(CH_2)_3 - NMe_2$

RN 251356-73-7 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)

$$^{\text{H}}_{\text{N}}$$
 $^{\text{O}}_{\text{CH}}$ $^{\text{H}}_{\text{N}}$ $^{\text{Me}}_{\text{Me}}$ $^{\text{(CH}_2)}_{3}$ $^{\text{NMe}_2}$

RN 251356-74-8 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

$$H$$
 CH
 N
 Me
 CH_2
 CH_2
 Me
 CH_2
 Me
 CH_2
 Me
 Me

RN 251356-75-9 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-(9CI) (CA INDEX NAME)

$$H_2N-S$$
 H_2N-S
 H

RN 251356-76-0 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & \\ i \text{-PrNH} - S & \\ & & \\ O & & \\ & & \\ O & & \\ &$$

RN 251356-77-1 CAPLUS

CN Morpholine, 4-[[3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\$$

RN 251356-78-2 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo-(9CI) (CA INDEX NAME)

RN 342641-60-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Br
$$CH \longrightarrow Me$$
 $C-NH-CH_2-CH_2-NMe_2$

RN 342641-61-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Ph
$$\stackrel{H}{\stackrel{N}{\stackrel{O}{\longrightarrow}}}$$
 $\stackrel{O}{\stackrel{H}{\stackrel{N}{\longrightarrow}}}$ $\stackrel{Me}{\stackrel{C-NH-CH_2-CH_2-NMe_2}{\longrightarrow}}$

RN 342641-62-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ &$$

RN 342641-63-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Br
$$\stackrel{H}{\sim}$$
 $\stackrel{O}{\sim}$ $\stackrel{H}{\sim}$ $\stackrel{Me}{\sim}$ $\stackrel{C-NH-CH_2-CH_2-NEt_2}{\mid}$

RN 342641-64-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-65-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-66-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(2-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

OMe

H
N
O
H
N
Me

$$C-NH-CH_2-CH_2-NMe_2$$

RN 342641-67-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-(3-methoxyphenyl)-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(dimethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-68-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & H & O & H & Me \\ \hline Ph & CH & Me & C-NH-CH_2-CH_2-NEt_2 \\ & \parallel & O & \\ \end{array}$$

RN 342641-69-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-70-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Ph
$$\stackrel{H}{\sim}$$
 $\stackrel{O}{\sim}$ $\stackrel{H}{\sim}$ $\stackrel{Me}{\sim}$ $\stackrel{C-NH-CH_2-CH_2-NEt_2}{\mid\mid}$

RN 342641-72-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-73-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-74-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[6-(3,5-dichlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-75-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-76-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-77-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-6-(3-pyridinyl)-3H-indol-3-yl-idene]methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl= (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O & H & Me \\ \hline & CH & N & Me \\ \hline & Me & C-NH-(CH_2)_3-NMe_2 \\ \hline & O & \\ \end{array}$$

RN 342641-78-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-N-[3-(dimethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Ph
$$CH \longrightarrow Me$$
 $C-NH-(CH_2)_3-NMe_2$

RN 342641-79-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-5-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Ph
$$CH \longrightarrow Me$$
 $C-NH-(CH_2)_3-NEt_2$

RN 342641-80-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)propyl]-5-[(1,2-dihydro-2-oxo-6-phenyl-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

RN 342641-81-0 CAPLUS

CN 1H-Indole-4-carboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[4-[[[3-(diethylamino)propyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-(9CI) (CA INDEX NAME)

RN 342641-82-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Br
$$CH \longrightarrow Me$$
 $CH \longrightarrow Me$ $C-NH-(CH2)3-NEt2$

RN 342641-83-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

RN 342641-84-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(diethylamino)propyl]-2,4-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

RN 342641-85-4 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-bis(1-methylethyl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

RN 342641-87-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

RN 342641-88-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-butylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-89-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[2-methoxy=5-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-91-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[6-(4-ethylphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-92-3 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[6-(2,4-dimethoxyphenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-93-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-6-[3-(1-methylethyl)phenyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-(9CI) (CA INDEX NAME)

RN 342641-94-5 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl--(9CI) (CA INDEXNAME)

$$\begin{array}{c|c} H & O & H & Me \\ \hline & CH & N & Me \\ \hline & C-NH-CH_2-CH_2-NEt_2 \\ & | & O \\ \hline & O \\ \end{array}$$

RN 342641-95-6 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)

$$HO_2C$$
 H
 N
 O
 H
 N
 Me
 $C-NH-CH_2-CH_2-NEt_2$
 O

RN 342641-96-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
 & H & O & H & Me \\
 & Me & C & O & \\
 & & NH & \\
 & & CH_2 & \\
 & CH_2 & \\$$

RN 342641-97-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342641-98-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-[(3-pyridinylamino)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 342642-01-7 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[[5-[(dimethylamino)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4dimethyl- (9CI) (CA INDEX NAME)

RN 342642-02-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[5-[[(3-chlorophenyl)amino]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

C1
$$NH-S$$
 $CH-CH_2-CH_2-NEt_2$

RN 342642-09-5 CAPLUS

CN Glycine, N-[[5-[[1,2-dihydro-4-methyl-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 342642-10-8 CAPLUS

CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

RN 342642-11-9 CAPLUS

CN Glycine, N-[[5-[[1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

2000:688215 CAPLUS

DOCUMENT NUMBER:

133:252306

TITLE:

Preparation of indolinones as protein kinase

inhibitors.

INVENTOR(S):

Tang, Peng Cho; Sun, Li; Mcmahon, Gerald; Miller, Todd Anthony; Shirazian, Shahrzad; Wei, Chung Chen; Harris,

G. Davis; Xiaoyuan, Li; Liang, Congxin

PATENT ASSIGNEE(S):

Sugen, Inc., USA

SOURCE:

PCT Int. Appl., 245 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO. DATE

```
______
                     A1
                           20000928
                                        WO 2000-US7704 20000322
    WO 2000056709
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
            CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
            ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
            LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
            SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
            ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
            DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
            CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    EP 1165513
                      A1
                         20020102
                                        EP 2000-916622
                                                          20000322
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
                                       US 1999-125945P P 19990324
PRIORITY APPLN. INFO.:
                                       US 1999-127863P P
                                                          19990405
                                       US 1999-131192P P
                                                         19990426
                                       US 1999-132243P P
                                                          19990503
                                       WO 2000-US7704
                                                       W 20000322
                        MARPAT 133:252306
OTHER SOURCE(S):
GI
```

Title compds., e.g. [I; m, n = 0, 1; Q = (JR11)m; Q1 = (DR6)n; when n = 1, then A, B, D, E, F = C, N; .ltoreq.3 of A, B, D, E, F = N; when m = 1, then G, H, J, K, L = C, N; .gtoreq.1 and .ltoreq.3 of G, H, J, K, L = N; when n = 0, then A = C, N, B, F = C, N, NH, O, S; E = C, N, O, S; when m = O, then G = C, N, H, K, l = C, N, NH, O, S; R1-R13 = H, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, OH, alkoxy, SH, alkylthiol, aryloxy, amino, etc.; R4R5 or R5R6 or R6R7 or R7R8 = atoms to form a 5-6 membered (hetero)aryl ring; with addnl. provisos], were prepd. Thus, 6-pyridin-3-yl-1,3-dihydroindol-2-one (prepn. given), 4-methoxy-3-thien-2-ylbenzaldehyde, and piperidine were refluxed overnight in EtOH to give 15% 3-(4-methoxy-3-thien-2-ylbenzylidene)-6-pyridin-3-yl-1,3-dihydroindol-2-one. Tested title compds. inhibited HER2 kinase with IC50 = 16.4 .mu.M to .gtoreq.100 .mu.M.

IT 251356-74-8P 295799-29-0P 295799-47-2P 295799-51-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of indolinones as protein kinase inhibitors)

Ι

RN 251356-74-8 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

$$HO-CH_2-CH_2$$
 $HO-CH_2-CH_2$
 $HO-C$

RN 295799-29-0 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-[2-[3-(1-methylethyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)

RN 295799-47-2 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)

$$H$$
 N
 CH
 Me
 $(CH2)3-NMe2$

RN 295799-51-8 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(2-thienyl)- (9CI) (CA INDEX NAME)

IT 251356-61-3P 251356-63-5P 251356-65-7P 251356-66-8P 251356-67-9P 251356-68-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of indolinones as protein kinase inhibitors)

RN 251356-61-3 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-(9CI) (CA INDEX NAME)

RN 251356-63-5 CAPLUS

CN 2H-Indol-2-one, 5-bromo-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

Br
$$\stackrel{\text{H}}{\longrightarrow}$$
 $\stackrel{\text{O}}{\longrightarrow}$ $\stackrel{\text{H}}{\longrightarrow}$ $\stackrel{\text{Me}}{\longrightarrow}$ $\stackrel{\text{Me}}{\longrightarrow}$ $\stackrel{\text{CH}_2)}{\longrightarrow}$ $\stackrel{\text{N}}{\longrightarrow}$ $\stackrel{\text{N}}{\longrightarrow}$ $\stackrel{\text{N}}{\longrightarrow}$

RN 251356-65-7 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

OMe

H

$$CH$$
 N
 Me
 $(CH_2)_3$
 NMe_2

RN 251356-66-8 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

MeO
$$\begin{array}{c} H \\ N \\ \end{array}$$
 $\begin{array}{c} CH \\ \end{array}$ $\begin{array}{c} H \\ N \\ \end{array}$ $\begin{array}{c} Me \\ \end{array}$ $\begin{array}{c} (CH_2)_3 - NMe_2 \\ \end{array}$

RN 251356-67-9 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

MeO
$$H$$
 N O H Me CH Me $(CH2)3-NMe2$

RN 251356-68-0 CAPLUS

CN 2H-Indol-2-one, 5-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

$$C1$$
 H
 CH
 N
 Me
 $CH_2)_3-NMe_2$

REFERENCE COUNT:

31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:

1999:764021 CAPLUS

DOCUMENT NUMBER:

132:12257

TITLE:

Preparation of pyrrole substituted 2-indolinone

protein kinase inhibitors

INVENTOR(S):

Tang, Peng Cho; Sun, Li; McMahon, Gerald

PATENT ASSIGNEE(S):

Sugen, Inc., USA

SOURCE:

PCT Int. Appl., 240 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.				KIND		DATE			APPLICATION NO.					DATE				
	WO	0 9961422			A1		19991202			WO 1999-US12069					19990528			
		W:	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,
			DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,
			ΚE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,
			MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,

```
TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
             ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
             CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                            CA 1999-2314156 19990528
     CA 2314156
                       AA
                             19991202
     AU 9944102
                       A1
                             19991213
                                            AU 1999-44102
                                                              19990528
                                            EP 1999-927120
                                                              19990528
     EP 1082305
                       Α1
                             20010314
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     BR 9910792
                             20020129
                                            BR 1999-10792
                                                              19990528
                       Α
     US 6395734
                       B1
                             20020528
                                            US 1999-322297
                                                              19990528
     JP 2002516310
                       T2
                             20020604
                                            JP 2000-550828
                                                              19990528
    NO 2000005916
                             20010129
                                            NO 2000-5916
                                                              20001122
                       Α
PRIORITY APPLN. INFO.:
                                         US 1998-87310P
                                                           P
                                                              19980529
                                         US 1999-116106P
                                                           P
                                                              19990115
                                         WO 1999-US12069
                                                              19990528
```

OTHER SOURCE(S): MARPAT 132:12257

$$\begin{array}{c|c} & \text{Me} & \text{CO}_2H \\ & & \\ & N \\ & H \end{array}$$

AB The present invention relates to 5-(2-oxo-1,2-dihydroindol-3ylidenemethyl)-1H-pyrrol-3-ylalkanoic acid derivs. (I) [where R1 and R7 = independently H, (cyclo)alkyl, alkenyl, alkynyl, aryl, OH, alkoxy, carboxy, acetyl, (thio)amido, (trihalomethane)sulfonyl, etc.; R2 = H, halo, (cyclo) alkyl, (hetero) aryl, or heteroalicyclic; R3, R4, R5, R6, R8, R9, R10 = independently H, (cyclo)alkyl, trihaloalkyl, alkenyl, alkynyl, (hetero)aryl(oxy), heteroalicyclic, OH, alkoxy, SH, alkylthio, arylthio, sulfinyl, sulfonyl, sulfonamido, carbonyl, carboxy, amido, CN, NO2, halo, (thio)carbamyl, (un)substituted amino, etc.] which modulate the activity of protein kinases and are useful in the prevention and treatment of protein kinase related cellular disorders, such as cancer. Thus, 2,4-dimethyl-5-ethoxycarbonyl-3-(2-ethoxycarbonylethyl)pyrrole was deprotected using NaOH to form 3-(2-carboxyethyl)-2,4-dimethylpyrrole (100%) and the product C-5 formylated (two methods given for 86% and 90% yield, resp.). Reaction with 2-oxindole in EtOH and pyrrolidine or in aq. NaOH yielded II (88% and 91%, resp.), which reduced the av. size of C6 human glioma and melanoma tumors s.c. implanted in mice by 80-85%. II,

when administered orally, demonstrated notably superior efficacy compared to structurally similar analogs.

IT 251356-61-3P 251356-63-5P 251356-64-6P 251356-65-7P 251356-66-8P 251356-67-9P 251356-68-0P 251356-69-1P 251356-70-4P

251356-71-5P 251356-72-6P 251356-73-7P

251356-74-8P 251356-75-9P 251356-76-0P

251356-77-1P 251356-78-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of 5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-ylalkanoic acid protein kinase inhibitors as antitumor agents)

RN 251356-61-3 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

RN 251356-63-5 CAPLUS

CN 2H-Indol-2-one, 5-bromo-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

Br
$$\stackrel{H}{\sim}$$
 $\stackrel{O}{\sim}$ $\stackrel{H}{\sim}$ $\stackrel{Me}{\sim}$ $\stackrel{Me}{\sim}$ $\stackrel{(CH_2)}{\sim}$ $\stackrel{3}{\sim}$ $\stackrel{NMe_2}{\sim}$

RN 251356-64-6 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-phenyl- (9CI) (CA INDEX NAME)

Ph
$$\stackrel{H}{\stackrel{N}{\stackrel{}}}$$
 $\stackrel{O}{\stackrel{}}$ $\stackrel{H}{\stackrel{N}{\stackrel{}}}$ $\stackrel{Me}{\stackrel{}}$ $\stackrel{Me}{\stackrel{}}$ $\stackrel{(CH_2)}{\stackrel{3}{\stackrel{}}}$ $\stackrel{NMe_2}{\stackrel{}}$

RN 251356-65-7 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

10081147

OMe

H

$$CH$$
 N
 Me
 CH_{2}
 Me
 CH_{2}
 Me
 Me

RN 251356-66-8 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

RN 251356-67-9 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

MeO
$$H$$
 N Me CH N Me $(CH2)3-NMe2$

RN 251356-68-0 CAPLUS

CN 2H-Indol-2-one, 5-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

$$C1$$
 H
 CH
 H
 Me
 $CH_2)_3-NMe_2$

RN 251356-69-1 CAPLUS

CN 2H-Indol-2-one, 6-chloro-3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

$$C1$$
 H
 O
 H
 N
 Me
 CH
 Me
 $(CH2)3-NMe2$

RN 251356-70-4 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-methoxy- (9CI) (CA INDEX NAME)

MeO
$$\stackrel{H}{\sim}$$
 $\stackrel{O}{\sim}$ $\stackrel{H}{\sim}$ $\stackrel{Me}{\sim}$ $\stackrel{Me}{\sim}$ $\stackrel{(CH_2)_3-NMe_2}{\sim}$

RN 251356-71-5 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-6-methoxy- (9CI) (CA INDEX NAME)

MeO
$$\stackrel{H}{\stackrel{N}{\stackrel{}}}$$
 $\stackrel{O}{\stackrel{}}$ $\stackrel{H}{\stackrel{}}$ $\stackrel{Me}{\stackrel{}}$ $\stackrel{Me}{\stackrel{}}$ $\stackrel{CH}{\stackrel{}}$ $\stackrel{Me}{\stackrel{}}$ $\stackrel{CH}{\stackrel{}}$ $\stackrel{Me}{\stackrel{}}$ $\stackrel{CH}{\stackrel{}}$ $\stackrel{Me}{\stackrel{}}$

RN 251356-72-6 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-methyl- (9CI) (CA INDEX NAME)

Me
$$CH \longrightarrow N$$
 Me $CH_2)_3 - NMe_2$

RN 251356-73-7 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)

$$H$$
 CH
 H
 Me
 Me
 $(CH2)3-NMe2$

RN 251356-74-8 CAPLUS

CN 2H-Indol-2-one, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-4-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

HO-
$$CH_2$$
- CH_2

Me

(CH₂) 3-NMe₂

RN 251356-75-9 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-(9CI) (CA INDEX NAME)

$$H_{2}N-S$$
 CH
 N
 Me
 $CH_{2}N-S$
 Me
 $CH_{2}N-S$
 Me
 $CH_{2}N-S$
 Me
 $CH_{2}N-S$
 Me
 $CH_{2}N-S$
 Me

RN 251356-76-0 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)

RN 251356-77-1 CAPLUS

CN Morpholine, 4-[[3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ &$$

RN 251356-78-2 CAPLUS

CN 1H-Indole-5-sulfonamide, 3-[[4-[3-(dimethylamino)propyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo-(9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ &$$

5

REFERENCE COUNT:

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

NEWS INTER

NEWS PHONE

NEWS WWW

Connecting via Winsock to STN

Welcome to STN International! Enter x:x LOGINID: SSSPTA1613SXW PASSWORD: TERMINAL (ENTER 1, 2, 3, OR ?):2 Welcome to STN International Web Page URLs for STN Seminar Schedule - N. America NEWS 2 Apr 08 "Ask CAS" for self-help around the clock NEWS Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area NEWS 3 NEWS 4 Apr 09 ZDB will be removed from STN NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available NEWS 9 Jun 03 New e-mail delivery for search results now available NEWS 10 Jun 10 MEDLINE Reload NEWS 11 Jun 10 PCTFULL has been reloaded NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment NEWS 13 Jul 22 USAN to be reloaded July 28, 2002; saved answer sets no longer valid Enhanced polymer searching in REGISTRY NEWS 14 Jul 29 NEWS 15 Jul 30 NETFIRST to be removed from STN NEWS 16 Aug 08 CANCERLIT reload NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN NEWS 18 Aug 08 NTIS has been reloaded and enhanced NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN IFIPAT, IFICDB, and IFIUDB have been reloaded NEWS 20 Aug 19 NEWS 21 The MEDLINE file segment of TOXCENTER has been reloaded Aug 19 NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced NEWS 23 Sep 03 JAPIO has been reloaded and enhanced NEWS 24 Sep 16 Experimental properties added to the REGISTRY file NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985 NEWS 28 Oct 21 EVENTLINE has been reloaded NEWS 29 Oct 24 BEILSTEIN adds new search fields NEWS 30 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN NEWS 31 Oct 25 MEDLINE SDI run of October 8, 2002 NEWS 32 Nov 18 DKILIT has been renamed APOLLIT NEWS 33 Nov 25 More calculated properties added to REGISTRY NEWS EXPRESS October 14 CURRENT WINDOWS VERSION IS V6.01, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002 NEWS HOURS STN Operating Hours Plus Help Desk Availability

Enter NEWS followed by the item number or name to see news on that specific topic.

CAS World Wide Web Site (general information)

Direct Dial and Telecommunication Network Access to STN

General Internet Information

Welcome Banner and News Items